ADCT · Adc Therapeutics SA
United States · RS rating 51 · As of 2026-11-03
| Price | 1.55 USD |
|---|---|
| 1-day change | +0.7% |
| RS rating (overall / 1M / 3M / 12M) | 51 / 96 / 95 / 14 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 39 / 34 / 42 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +86.7% |
| Sales growth Q/Q | +40.4% |
| Distance from 52-week high | +68.2% |
| Market cap (USD) | $503.7M |